DSI: Precision medicine in smoking cessation: nicotine metabolism genetics in nine clinical trials - Research Portal | Lancaster University

Home > Research > Projects > DSI: Precision medicine in smoking cessation: n...

View graph of relations

DSI: Precision medicine in smoking cessation: nicotine metabolism genetics in nine clinical trials

Project: Research

Status	Finished
Effective start/end date	1/03/18 → 28/02/22

Funding

Canadian Institute of Health research

Knight, Joanne (Principal Investigator)
Knight, Joanne (Principal Investigator)

Research outputs

Transferability Of Ancestry-Specific And Cross-Ancestry CYP2A6 Activity Genetic Risk Scores In African And European Populations
Research output: Contribution to Journal/Magazine › Journal article › peer-review
A genome-wide association study of nausea incidence in varenicline-treated cigarette smokers
Research output: Contribution to Journal/Magazine › Journal article › peer-review
Does sex alter the relationship between CYP2B6 variation, hydroxybupropion concentration and bupropion-aided smoking cessation in African Americans?: A moderated mediation analysis
Research output: Contribution to Journal/Magazine › Journal article › peer-review
Accuracy and applications of sequencing and genotyping approaches for CYP2A6 and homologous genes
Research output: Contribution to Journal/Magazine › Journal article › peer-review
Influence of CYP2A6 genetic variation, nicotine dependence severity, and treatment on smoking cessation success
Research output: Contribution to Journal/Magazine › Journal article › peer-review
Genotyping, characterization, and imputation of known and novel CYP2A6 structural variants using SNP array data
Research output: Contribution to Journal/Magazine › Journal article › peer-review
Associating CYP2A6 structural variants with ovarian and lung cancer risk in the UK Biobank: replication and extension
Research output: Contribution to Journal/Magazine › Journal article › peer-review